Evaluation of the Relative Efficacy of an Allograft used alone and that in Combination with Simvastatin in the Treatment of Human Periodontal Infrabony Defects – A Clinical and Radiological Study  by Kinra, P. et al.
  
75 
J T U Med Sc 2010; 5(2) 
 
 
Evaluation of the Relative Efficacy of an Allograft used alone 
and that in Combination with Simvastatin in the Treatment of 
Human Periodontal Infrabony Defects – A Clinical and 
Radiological Study 
  
Kinra P.1 MDS, Gupta H.1 MDS, Khan S.2 MDS,  
Mohammad Sami Ahmad3 Ph. D  
 
Department of Periodontics Punjab Government Dental College and Hospital Amritsar1, Department of 
Periodontics and Community Dentistry Aligarh Muslim University Aligarh2 India, College of Dentistry 
Taibah University Al Madinah Al Munawarah3 Kingdom of Saudi Arabia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Objectives 
Simvastatin has been found to cause increased bone formation in vitro and in animal studies. 
However, its effect on periodontal reconstruction in humans is yet to be determined. With 
this study an attempt was made to evaluate the effects of a combination of simvastatin drug 
with Demineralised Freeze-Dried Bone Allograft (DFDBA) and also to compare the efficacy 
of this combination with that of DFDBA alone in the treatment of human periodontal defects. 
Methods 
Fifteen patients with almost identical bilateral 2-walled or 3-walled infrabony defects were 
selected. Defects on the right side (Group A) were treated with the placement of DFDBA 
alone while those on the left side (Group B) were treated using a combination of DFDBA and 
a 10-8 M solution of the drug simvastatin. Two clinical parameters, namely probing pocket 
depth and clinical attachment level and one radiographic parameter, namely infrabony defect 
depth were measured preoperatively and 12 and 24 weeks postoperatively. 
Results 
DFDBA alone as well as the combination of DFDBA and simvastatin resulted in a highly 
significant mean reduction in probing depth, gain in clinical attachment level, and linear 
defect fill. The values of mean changes in parameters were significantly greater with the 
drug-graft combination in comparison with the graft alone.  
Conclusions  
Combination of DFDBA with a solution of simvastatin leads to significantly greater 
reduction in probing depth, gain in clinical attachment level, and linear defect fill than when 
the graft is used alone in the treatment of human periodontal infrabony defects. 
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Introduction 
 
rogressive destruction of the periodontal 
ligament and alveolar bone with pocket 
formation, recession, or both are the results of 
periodontitis. The ultimate goal of periodontal 
therapy is to regenerate lost periodontal tissue, 
which is directed towards a more coronal 
attachment of the periodontal fibres resulting in 
decreased probing depth, and improved bone 
support as evidenced radiographically. Now a 
day surgical procedures involving bone grafting 
are the most common forms of regenerative 
periodontal therapy and leads to predictable 
regeneration of bone, cementum, and 
functionally oriented new periodontal ligaments 
coronal to the base of a previous osseous defect1. 
One of the most commonly used grafts at 
present is Demineralized Freeze-Dried Bone 
Allograft (DFDBA). It is known to stimulate 
bone formation by the processes of 
osteoinduction2 as well as osteoconduction3. 
Implantation of defects with DFDBA usually 
results in a decrease in probing depth, gain in 
clinical attachment and reconstruction of hard 
tissue as represented by the formation of new 
bone and cementum4-6. 
The need to achieve greater regeneration an 
agent is used, which would not only inhibit 
resorption of the alveolar bone but also 
stimulate new bone formation. Simvastatin is a 
pharmacologic compound, which is widely used 
for the treatment of hypercholesterolaemia. It 
belongs to a family of drugs called the statins 
and is an inhibitor of the enzyme HMG-CoA 
reductase, an important rate limiting enzyme of 
the mevalonate pathway7. It has been shown to 
markedly increase new bone formation and 
osteoblast numbers in vitro and also after 
systemic administration in animal models by 
activating the gene expression of BMP-28-9. A 
number of studies have concentrated on the 
effects of locally administered simvastatin on 
bone formation10. It has been seen that 
osteogenesis is enhanced by the local application 
of simvastatin in the calvaria of rats 11. Injectable 
simvastatin is seen to increase the thickness of 
edentulous buccal ridges and also result in new 
cementum formation in relation to 
experimentally created infrabony defects in 
beagle dogs12. Furthermore, subperiosteal 
injections of simvastatin in the region of 
experimentally induced periodontal breakdown 
in rats have resulted in lesser bone loss and 
attachment loss than controls13. Simvastatin has 
also been observed to have direct effects on 
human periodontal ligament cells in vitro. It has 
been shown to enhance the proliferation and 
metabolism of these cells in addition to 
promoting their activity of the enzyme alkaline 
phosphatase. These actions occur in a dose 
dependent manner and are seen to peak at a 
concentration of 10-8 M concentration of 
simvastatin14-15. Moreover, the systemic use of 
statins is associated with a reduced risk of tooth 
loss in individuals suffering from chronic 
periodontitis16. 
In the present study, an attempt has been made 
to evaluate clinically and radiographically the 
relative efficacy of an allograft (DFDBA) used 
alone and that in combination with a 10-8 M 
simvastatin in the treatment of human 
periodontal infrabony defects. 
 
Aim 
To compare DFDBA alone to DFDBA in 
combination with Simvastatin in the treatment 
of infrabony periodontal pockets. 
  
Materials and Methods 
 
The study was clinical trial with split mouth 
design. In this study fifteen patients (8 males 
and 7 females) showing evidence of almost 
identical bilateral two or three-walled infrabony 
defects, as determined by clinical and 
radiographic evaluation, were selected amongst 
those reporting to the Department of 
Periodontics, Punjab Government Dental 
College and Hospital, Amritsar, India. The 
patients selected were non-smokers, non-
alcoholics, and had no history of allergies or any 
systemic debilitating disease. All patients 
meeting the selection criteria were consecutively 
enrolled from February, 2008 to January, 2009. 
Prior to surgery, oral prophylaxis, occlusal 
equilibration, and routine laboratory 
investigations were performed. Their oral 
hygiene status was monitored and reviewed 
until it was achieved to a satisfactory level. 
The clinical parameters assessed were probing 
depth and attachment level. A customised 
acrylic stent was used for the clinical 
P 
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measurements Figure 1, Figure 217. 
Radiographically, the infrabony defect depth 
was ascertained using a standardised 
radiographic technique and by measuring from 
a fixed reference point (the cementoenamel 
junction of the involved tooth) to the most apical 
point at the base of the defect.  
 
 
Figure 1: Measurement of probing depth with a 
William’s calibrated periodontal probe after placing a 
customized acrylic stent.  
 
 
Figure 2: Measurement clinical attachment level 
with a William’s calibrated periodontal probe after 
placing a customized acrylic stent.  
 
 
Figure 3: Radiographic grid being used for the 
measurement of infrabony defect depth. 
 
 
Figure 4: The designated site of Group A with the 
exposed infrabony defect 
  
A grid with 1 mm X 1 mm calibrations and a 
Vernier calliper were used to make the 
measurements to an accuracy of one-tenths of a 
millimetre Figure 3. In this way, preoperative 
assessment of the above mentioned parameters 
was done. The infrabony defect on the right side 
of the patient’s mouth was designated as Group 
A while that on the left side was designated as 
Group B. Group A defects were treated by 
placement of DFDBA and Group B defects were 
treated by placement of DFDBA in combination 
with a 10-8 M solution of simvastatin. The 
surgical procedures were performed by a single 
operator and both pre and post results were 
measured by another operator who was 
unaware of which side received DFDBA alone 
or in combination with simvastatin. The patients 
selected were living nearby hospital so they 
should visit on appointment date. The full 
addresses as well as mobile numbers were also 
recorded to inform if they did not turn on 
appointment given.   
 
Preparation of the drug solution  
 
The molecular weight of simvastatin is 418.57. 
To prepare a 10-8 M solution of simvastatin, 4.18 
X 10-3 mg of pure simvastatin in 1 litre of water 
is required. To obtain this concentration, 4.18 mg 
of pure simvastatin in powder form was 
thoroughly mixed with 1000 ml of water. 0.2 ml 
of this solution was taken and water was added 
to it to achieve a total volume of 200 ml. This 
solution was incorporated into the DFDBA 
material prior to placement in Group B defects. 
The patients were premedicated using diazepam 
(10 mg/2 ml injection intramuscularly) and 
glycopyrrolate (0.3 mg/3 ml injection 
intramuscularly) 45 minutes before the 
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procedure. A Kirkland flap was reflected 
following the administration of a local 
anaesthetic solution (lignocaine hydrochloride 
2% with adrenaline 1:200,000). The exposed 
defect was debrided so that it was prepared 
prior to the placement of graft alone in case of 
Group A or the graft in combination with 
simvastatin in case of group B Figure 4, Figure 
7. A suture needle was then passed through the 
buccal and lingual flaps. After the placement of 
the designated material in the defect Figure 5, 
Figure 8 the flap was approximated by tying a 
knot so as to complete the interrupted 
interdental suture Figure 6, Figure 9. Antibiotic 
therapy (amoxicillin 250 mg + cloxacillin 250 mg 
+ 60 million lactobacillus spores- Capsule 
Numox-LB, Jenburkt) three times a day for 1 
week and an anti-inflammatory agent 
(Ibuprofen 400 mg- Tablet Brufen, Knoll) thrice 
daily for 3 days were prescribed 
postoperatively. 
 
Figure 5: The Group A infrabony defect after 
placement of DFDBA 
 
 
Figure 6: The operated site after suturing 
 
The patients were advised to follow dietary 
instructions strictly and perform adequate 
plaque control by rinsing with 15 ml of a 0.12% 
chlorhexidine gluconate mouthwash (Periogard, 
Colgate) twice daily for two weeks 
postoperatively. Sutures were removed one 
week after surgery and postoperative 
assessment of the clinical and radiographic 
parameters was done at 12 and 14 week. 
 
 
Figure 7: The designated site of Group B with the 
exposed infrabony defect 
 
 
Figure 8: The Group B infrabony defect after 
placement of the combination of DFDBA  
and simvastatin solution 
 
 
Figure 9: The operated site after suturing 
 
Results 
 
It was observed that both DFDBA and 
simvastatin possessed excellent handling 
characteristics. It was easy to manipulate, and 
well tolerated by all patients, with no clinically 
observed adverse tissue reaction, infection, signs 
of delayed healing or rejection during the course 
of the study. Postoperative assessments for the 
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parameters were done at 12 weeks and 24 weeks 
respectively. The mean values of probing pocket 
depth Table 1, clinical attachment level Table 2, 
and infrabony defect depth Table 3 at the three 
points in time were evaluated. The data were 
subjected to analyze statistically by student’s t-
test and ANOVA approach. To evaluate the 
relative efficacy of the two materials used, 
Student’s t-test (for paired samples) was applied 
since the observations at the two points in time 
were expected to be closely related to each other. 
On analyzing the clinical parameter of probing 
pocket depth in the two groups it was seen that 
a highly significant reduction in probing pocket 
depth took place with both materials at 12 
weeks, 24 weeks as well as between 12 and 24 
weeks postoperatively (p< 0.01) as shown in 
Table 4 
Similarly both groups showed a statistically 
highly significant gain in clinical attachment 
level and radiographically observed linear 
defect fill (p<0.01) at 12 weeks, 24 weeks as well 
as between 12 and 24 weeks postoperatively 
(Table 5, Table 6). On comparative evaluation of 
the two groups, it was seen that the use of the 
combination of DFDBA and simvastatin 
exhibited a greater reduction in probing depth 
than DFDBA used alone at the end of 12 weeks 
and 24 weeks postoperatively and the difference 
between the two groups was statistically highly 
significant. However, the reduction in probing 
depth seen with in Group A was equal to that 
seen in Group B between the 12 and 24 weeks 
postoperative appointments (Table 7, Figure 
10). 
The mean gain in clinical attachment was also 
greater with DFDBA in combination with 
simvastatin as compared to DFDBA alone at 12 
weeks and 24 weeks postoperatively. This 
difference was statistically significant. But the 
mean gain in clinical attachment level between 
12 and 24 weeks was non-significantly greater 
with DFDBA alone than DFDBA in combination 
with simvastatin (Table 7, Figure 11). A similar 
trend was observed in the radiographic 
parameter of linear defect fill (Table 7, Figure 
12)
 
Table 1: Measurement of probing pocket depth in mm using DFDBA alone (Group-A) and DFDBA in 
combination with simvastatin (Group-B) 
 
No. 
Probing pocket depth 
Demineralized Freeze-Dried Bone Allograft 
(DFDBA) (GROUP-A) 
DFDBA with Simvastatin (GROUP-B) 
Pre-
operative 
12-weeks 
post-
operative 
24-weeks 
post-
operative 
Pre- 
operative 
12-weeks 
post-
operative 
24-weeks 
post-
operative 
1. 5 4 2 6 1 1 
2. 5 3 2 6 2 1 
3. 5 4 3 6 3 2 
4. 6 3 2 6 2 2 
5. 6 4 3 7 2 1 
6. 6 3 2 5 3 1 
7. 6 3 2 5 2 2 
8. 7 4 3 8 2 1 
9. 6 4 3 8 3 2 
10. 6 3 3 6 3 2 
11. 6 4 3 5 3 1 
12. 7 5 3 8 4 2 
13. 7 4 3 7 3 2 
14. 9 5 4 9 4 3 
15. 7 5 4 8 3 1 
MEANr SEm 6.27 ± 0.27 3.87 ± 0.19 2.80 ± 0.17 6.67 ± 0.33 2.67 ± 0.21 1.60 ± 0.16 
Mohammad Sami Ahmad et al 
 
 
80 
J T U Med Sc 2010; 5(2) 
Table 2: Measurement of clinical attachment level in mm using DFDBA alone (Group-A) and DFDBA 
in combination with simvastatin (Group-B in) 
 
 
No. 
Clinical attachment level 
Demineralized Freeze-Dried Bone Allograft 
(DFDBA) (GROUP-A) 
DFDBA with Simvastatin (GROUP-B) 
Pre-
operative 
12-weeks 
post-
operative 
24-weeks 
post-
operative 
Pre-operative 12-weeks 
post-
operative 
24-weeks 
post-
operative 
1. 5 3 2 4 1 1 
2. 5 3 2 5 2 2 
3. 6 4 2 6 2 1 
4. 3 3 2 3 1 1 
5. 6 4 2 7 3 1 
6. 5 2 2 6 2 1 
7. 5 4 3 6 3 2 
8. 7 3 2 7 2 1 
9. 6 3 2 7 2 1 
10. 6 4 3 5 3 2 
11. 5 3 3 5 2 1 
12. 5 4 2 6 3 2 
13. 6 3 3 6 2 1 
14. 7 4 3 8 3 2 
15. 7 3 3 8 2 1 
MEANr SEm 5.60 ± 0.27 3.33 ± 0.16 2.40 ± 0.13 5.93 ± 0.36 2.20 ± 0.17 1.33 ± 0.13 
 
Table 3: Radiographically ascertained infrabony defect depth in mm using DFDBA alone (Group-A) 
and DFDBA in combination with simvastatin (Group-B) 
 
 
No. 
   Infrabony defect depth 
Demineralized Freeze-Dried Bone Allograft 
(DFDBA) (GROUP-A) 
DFDBA with Simvastatin (GROUP-B) 
Pre-operative 12-weeks 
post-
operative 
24-weeks 
post-
operative 
Pre-operative 12-weeks 
post-
operative 
24-weeks 
post-
operative 
1. 5.8 3.9 2.1 6.2 1.3 0.9 
2. 6.1 3.4 2.6 6.4 2.1 1.3 
3. 7.1 4.3 2.9 7.3 2.1 1.2 
4. 5.8 4.7 3.8 6.7 2.8 1.4 
5. 7.1 5.3 2.3 6.9 3.6 1.1 
6. 6.0 2.8 2.6 6.3 2.2 0.9 
7. 6.3 4.9 3.2 6.9 2.1 1.0 
8. 7.8 3.4 2.6 7.6 2.4 1.1 
9. 8.1 3.9 2.2 7.8 2.8 1.4 
10. 8.2 6.4 4.7 7.3 3.9 3.1 
11. 6.4 4.9 3.6 6.9 2.9 1.2 
12. 7.3 4.8 3.5 7.6 3.2 2.1 
13. 8.2 6.4 3.8 7.4 3.8 2.2 
14. 8.2 5.1 3.7 8.4 2.8 1.9 
15. 7.3 3.4 2.7 7.0 2.9 1.8 
MEANr SEm 7.05 ± 0.24 4.51 ± 0.28 3.09 ± 0.19 7.11 ± 0.16 2.73 ± 0.19 1.51 ± 0.16 
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Table 4: Reduction in probing pocket depth in mm using DFDBA alone (Group-A) and DFDBA in 
combination with simvastatin (Group-B) 
 
 
 
No. 
Reduction in probing pocket depth 
 Demineralized Freeze-Dried Bone Allograft 
(DFDBA) (GROUP-A) 
DFDBA with Simvastatin (GROUP-B) 
Pre-operative 
to 12 weeks 
post-operative  
Pre-operative 
to 24 weeks 
post-
operative 
12 weeks to 
24 weeks 
post-
operative  
Pre-operative 
to 12 weeks 
post-operative 
Pre-operative 
to 24 weeks 
post-
operative 
12 weeks to 24 
weeks post-
operative 
1. 1 3 2 5 5 0 
2. 2 3 1 4 5 1 
3. 1 2 1 3 4 1 
4. 3 4 1 4 4 0 
5. 2 3 1 5 6 1 
6. 3 4 1 2 4 2 
7. 3 4 1 3 3 0 
8. 3 4 1 6 7 1 
9. 2 3 1 5 6 1 
10. 3 3 0 3 4 1 
11. 2 3 1 2 4 2 
12. 2 4 2 4 6 2 
13. 3 4 1 4 5 1 
14. 4 5 1 5 6 1 
15. 2 3 1 5 7 2 
MEANr SEm 2.40 ± 0.21 3.47 ± 0.19 1.07 ± 0.12 4.00 ± 0.31 5.07 ± 0.32 1.07 ± 0.18 
Table 5: Measurement of gain in clinical attachment level in mm using dfdba alone (Group-A) and 
DFDBA in combination with simvastatin (Group-B) 
 
 
 
No. 
Gain in clinical attachment level 
Demineralized Freeze-Dried Bone Allograft 
(DFDBA) (GROUP-A) 
DFDBA with Simvastatin (GROUP-B) 
Pre-operative 
to 12 weeks 
post-
operative  
Pre-operative 
to 24 weeks 
post-
operative 
12 weeks to 
24 weeks 
post-
operative  
Pre-operative 
to 12 weeks 
post-
operative 
Pre-operative 
to 24 weeks 
post-
operative 
12 weeks to 
24 weeks 
post-
operative  
1. 2 3 1 3 3 0 
2. 2 3 1 3 3 0 
3. 2 4 2 4 5 1 
4. 0 1 1 2 2 0 
5. 2 4 2 4 6 2 
6. 3 3 0 4 5 1 
7. 1 2 1 3 4 1 
8. 4 5 1 5 6 1 
9. 3 4 1 5 6 1 
10. 2 3 1 2 3 1 
11. 2 2 0 3 4 1 
12. 1 3 2 3 4 1 
13. 3 3 0 4 5 1 
14. 3 4 1 5 6 1 
15. 4 4 0 6 7  1  
MEANr SEm 2.27 ± 0.28 3.20 ± 0.26 0.93 ± 0.18 3.73 ± 0.30 4.60 ± 0.38 0.87 ± 0.13 
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Table 6: Radiographically ascertained linear defect fill in mm using DFDBA alone (Group-A) and 
DFDBA in combination with simvastatin (Group-B) 
 
 
 
No. 
Linear defect fill 
Demineralized Freeze-Dried Bone Allograft 
(DFDBA) (GROUP-A) 
DFDBA with Simvastatin (GROUP-B) 
Pre-
operative to 
12 weeks 
post-
operative  
Pre-operative 
to 24 weeks 
post-operative 
12 weeks to 
24 weeks 
post 
operative  
Pre-
operative to 
12 weeks 
post-
operative 
Pre-operative 
to 24 weeks 
post-
operative 
12 weeks to 
24 weeks 
post-
operative  
1. 1.9 3.7 1.8 4.9 5.3 0.4 
2. 2.7 3.5 0.8 4.3 5.1 0.8 
3. 2.8 4.2 1.4 5.2 6.1 0.9 
4. 1.1 2.0 0.9 3.9 5.3 1.4 
5. 1.8 4.8 3.0 3.3 5.8 2.5 
6. 3.2 3.4 0.2 4.1 5.4 1.3 
7. 1.4 3.1 1.7 4.8 5.9 1.1 
8. 4.4 5.2 0.8 5.2 6.5 1.3 
9. 4.2 5.9 1.7 5.0 6.4 1.4 
10. 1.8 3.5 1.7 3.4 4.2 0.8 
11. 1.5 2.8 1.3 4.0 5.7 1.7 
12. 2.5 3.8 1.3 4.4 5.5 1.1 
13. 1.8 4.4 2.6 3.6 5.2 1.6 
14. 3.1 4.5 1.4 5.6 6.5 0.9 
15. 3.9 4.6 0.7 4.1 5.2 1.1 
MEANr SEm 2.54 ± 0.27 3.96 ± 0.26 1.42 ± 0.19 4.39 ± 0.18 5.61 ± 0.16 1.22 ± 0.13 
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Table 7: Comparison of demineralized freeze-dried bone allograft (DFDBA) alone (Group-A) and DFDBA in combination with simvastatin 
(Group-B) for the chosen parameters (in mm) 
Parameter Group A Group B Mean Difference Group B – Group A 
 
Pre-operative 
to 12 weeks 
post 
operative 
Pre-operative 
to 24 weeks 
post 
operative 
12 weeks to 
24 weeks 
post 
operative 
Pre-operative 
to 12 weeks 
post 
operative 
Pre-operative 
to 24 weeks 
post 
operative 
12 weeks to 
24 weeks 
post 
operative 
Pre-operative 
to 12 weeks 
post 
operative 
Pre-
operative to 
24 weeks 
post 
operative 
12 weeks to 
24 weeks 
post 
operative 
Mean reduction in 
probing depth 2.40 ± 0.21 3.47 ± 0.19 1.07 ± 0.12 4.00 ± 0.31 5.07 ± 0.32 1.07 ± 0.18 
1.60 ± 0.38 
(4.262**) 
1.60 ± 0.37 
(4.331**) 
0.00 ± 0.22 
(0.000NS) 
Mean gain in clinical 
attachment level 2.27 ± 0.28 3.20 ± 0.26 0.93 ± 0.18 3.73 ± 0.30 4.60 ± 0.38 0.87 ± 0.13 
1.47 ± 0.41 
(3.549**) 
1.40 ± 0.46 
(3.059**) 
-0.067 ± 
0.23 
(0.296NS) 
Mean linear defect fill 2.54 ± 0.27 3.96 ± 0.26 1.42 ± 0.19 4.39 ± 0.18 5.61 ± 0.16 1.22 ± 0.13 1.85 ± 0.33 (5.660**) 
1.65 ± 0.30 
(5.456**) 
-0.20 ± 0.23 
(0.886NS) 
 
@  : Represents mean ± standard error of mean 
$  : Values within parenthesis indicate paired ‘t’ ratios for testing significance of differences 
**  : Values are statistically significant at 1% probability level 
*   : Values are statistically significant at 5% probability level 
NS  : Values are statistically non significant at both 5% and 1% probability level
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Figure 10:  Showing Reduction in Probing Pocket Depth Using DFDBA 
Alone (Group A) and DFDBA  in Combination with Simvastatin (Group 
B) (in mm) 
 
 
 
Figure 11: Showing Gain in Clinical Attachment Level Using DFDBA 
Alone (Group A) and DFDBA in Combination with Simvastatin (Group B) 
(in mm)
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Figure 12: Showing Linear Defect Fill (Ascertained 
Radiographically) Using  DFDBA Alone (Group A) 
and DFDBA in Combination with Simvastatin 
(Group B) (in mm).  
 
Discussion 
 
Periodontal disease is an inflammatory response 
in the periodontal tissues induced by 
microorganisms present in dental plaque which 
contribute to tissue destruction, bone loss, and 
eventually tooth loss18. Periodontal therapy is 
aimed at the restoration of tissues destroyed by 
this disease process. Demineralised Freeze-
Dried Bone Allograft (DFDBA) is a widely used 
graft material because it is safe, easy to handle, 
and purported osteoinductive and 
osteoconductive properties2-3. During the 
manufacturing of DFDBA, demineralization of 
bone exposes bone morphogenetic proteins 
(BMPs), which induce new bone formation in 
the recipient connective tissue19. The addition of 
well-tolerated pharmacologic agents to a graft 
material enhance its properties seems to be a 
cost-effective and efficient approach towards 
achieving greater regeneration. Simvastatin, an 
inhibitor of the mevalonate pathway, is known 
to have a long history of systemic use for the 
treatment of hypercholesterolaemia without 
significant adverse events20. However, 
periodontal therapy necessitates a focussed 
effect in specific defects, suggesting the 
importance of local application of such an agent 
in combination with a graft material. This is one 
of the earliest studies investigating the effects of 
simvastatin on periodontal reconstruction in 
humans. 
Reduction in probing pocket depth on analyzing 
the results, the mean reductions in probing 
depth in both groups were found to be 
statistically significant at 12 weeks, 24 weeks as 
well as between 12 and 24 weeks 
postoperatively. The reduction achieved in 
Group B (combination of DFDBA and 
simvastatin) was significantly higher than that 
in Group A (DFDBA alone) at 12 weeks and 24 
weeks. However, the values of reduction of 
probing pocket depth between 12 and 24 weeks 
were equal for both groups.  
Gain in clinical attachment level showing a 
similar trend for this parameter, values of mean 
gain in attachment level for both Group A and 
Group B were statistically highly significant at 
12 weeks, 24 weeks, and between 12 and 24 
weeks. On comparing the results of the two 
groups the mean gain in attachment level was 
found to be significantly greater at 12 and 24 
weeks with the combination of graft and 
simvastatin. But the mean gain in attachment 
level was slightly greater with the use of the 
graft alone between 12 and 24 weeks. However, 
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this difference was found to be statistically non-
significant. 
Linear defect fill as with reduction in probing 
depth and gain in attachment level, linear defect 
fill was found to be statistically highly 
significant in both groups at all time intervals. 
At 12 and 24 weeks, the combination of the graft 
and simvastatin yielded a significantly greater 
linear defect fill than when the graft was used 
alone. But between 12 and 24 weeks, the mean 
linear defect fill was non-significantly greater in 
defects treated with the graft alone. 
The significantly greater reduction in probing 
pocket depth with the adjunctive use of 
simvastatin in the present study may have a 
logical basis in the findings of Davignon and 
Laaksonen who reported that it possesses 
biologically significant antioxidant and anti-
inflammatory properties and that’s why its 
administration reduces the plasma levels of 
inflammatory markers like C-reactive protein 
(CRP)21. These properties may have contributed 
to a greater reduction in probing pocket depth 
by continued facilitation of tissue healing and 
shrinkage. The greater linear defect fill observed 
with the combination of DFDBA and DFDBA 
may be attributed to the action of simvastatin on 
bone metabolism. Products of the mevalonate 
pathway, besides synthesizing cholesterol, are 
also responsible for the prenylation of some 
small GTPases22. Since such prenylation is of 
importance for the activation and survival of 
osteoclasts, the inhibition of small GTPases by 
simvastatin may impede osteoclast function and 
inhibit bone resorption23. In addition to being an 
inhibitor of bone resorption it has been shown to 
be among the most potent agents in stimulating 
bone formation. It has been shown to promote 
bone formation by upregulating the gene 
expression of BMP-28. The evidence in favour of 
interaction of simvastatin and BMP-2 has been 
strengthened by the finding that noggin, a BMP 
antagonist, decreases bone formation stimulated 
by both BMP and Simvastatin24. Since both 
DFDBA and simvastatin promote bone 
formation mediated by BMPs, their combination 
is expected to have had a synergistic action on 
the parameter of linear defect fill in our study. It 
has also been demonstrated that simvastatin 
promotes the formation of vascular structure 
(neoangiogenesis) in vitro25. Moreover, it has 
been found to markedly enhance the expression 
of genes for vascular endothelial growth factor, 
which is involved in endochondral bone 
formation and stimulation of osteoblastic 
differentiation26.  
Studies involving animal models have 
consistently supported the upregulatory effect of 
simvastatin on bone formation10- 12. Human 
anabolic effects of this drug on bone have been 
elucidated in the form of increased bone mineral 
density in diabetes mellitus patients who were 
administered statins systemically for the 
correction of increased cholesterol levels27. 
Similarly, a significantly decreased risk of hip 
fractures has been observed in elderly 
individuals after being given statins orally for a 
period of three months to three years28. 
The trend observed in the gain in clinical 
attachment level in this study was similar to that 
in linear defect fill. This was to be expected since 
it has been demonstrated that soft tissue 
attachment follows successful reconstruction of 
hard tissue as represented by the formation of 
new bone and cementum5. 
Of particular interest are the values of mean 
changes observed in the 12 to 24 week 
postoperative period. For all the three 
parameters assessed, these values, although 
significant in both groups, were lower than the 
corresponding values of the preoperative to 12 
week postoperative period. It has been observed 
that maximal healing of the periodontal tissues 
takes place in the first three postoperative 
months. During this period, a fully 
epithelialized gingival crevice with a well-
defined epithelial attachment is formed and a 
functional arrangement of the supracrestal 
collagen fibres is established29. It has also been 
seen that following grafting, newly formed 
collagen fibre bundles are aligned parallel to the 
root surface three months after surgery and are 
inserted into the root surface at six months30. 
The values of mean gain in attachment level and 
mean defect fill with the combination of the 
drug + graft group were non-significantly lower 
than the graft alone group. This may suggest 
that simvastatin exerted the major portion of its 
potentiating effect on the regenerative action of 
DFDBA during the first 12 weeks 
postoperatively. 
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Conclusion 
 
The results of this study clearly indicate that 
simvastatin, in a concentration of 10-8 M, 
enhances the reconstructive action of DFDBA 
when the two materials are combined with each 
other for the treatment of periodontal infrabony 
defects in humans, as evidenced clinically and 
radiographically. These results present a valid 
premise for further long term studies to evaluate 
the potential effects of simvastatin in 
conjunction with regenerative materials for the 
treatment of periodontal osseous defects. 
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